Metallothionein: Early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma

被引:18
作者
Bruewer, M
Schmid, KW
Krieglstein, CF
Senninger, N
Schuermann, G
机构
[1] Univ Munster, Dept Gen Surg, D-48149 Munster, Germany
[2] Univ Essen Gesamthsch, Inst Pathol, D-45147 Essen, Germany
关键词
D O I
10.1007/s00268-002-6266-z
中图分类号
R61 [外科手术学];
学科分类号
摘要
Metallothioneins (MTs) are zinc-binding proteins whose overexpression may lead to sequestration of zinc ions and consequently to functional inactivation of the p53 tumor suppressor gene. The aim of the study was to investigate the potential role of MTs in the carcinogenesis of ulcerative colitis (UC) as well as possible effects on p53 function. The monoclonal antibodies E9 (anti-MT), DO-7, and 1801 (anti-p53) and the polyclonal antibody CM-1 (anti-p53) were used to stain formalin-fixed, paraffin-embedded colon specimens obtained from 14 patients with UC-associated colorectal carcinoma (CAC), 13 with high-grade dysplasia (HGD), 10 with low-grade dysplasia (LGD), and 30 with UC without dysplasia or carcinoma. Statistical significance (p < 0.05) was assessed using Fisher's exact test. Positive NIT staining (>20% of tumor, dysplastic, or epithelial cells) was found in most UC and LGD but in only a small percentage of HGD and CAC (p < 0.01 for CAC vs. UC and LGD vs. HGD). Positive p53 immunoreactivity was observed predominantly in HGD and CAC but not in LGD and UC (p < 0.01 for CAC vs. UC and HGD vs. LGD). In histologically normal tissue neighboring CAC, significant NIT expression was found in six of seven specimens with simultaneous lack of p53 expression. MT overexpression may represent an important early step in the development of CAC independent of p53 expression and should be investigated in the long term as an independent cancer risk factor in UC.
引用
收藏
页码:726 / 731
页数:6
相关论文
共 40 条
[1]  
AbdelMageed AB, 1997, CANCER GENE THER, V4, P199
[2]   WET AUTOCLAVE PRETREATMENT FOR ANTIGEN RETRIEVAL IN DIAGNOSTIC IMMUNOHISTOCHEMISTRY [J].
BANKFALVI, A ;
NAVABI, H ;
BIER, B ;
BOCKER, W ;
JASANI, B ;
SCHMID, KW .
JOURNAL OF PATHOLOGY, 1994, 174 (03) :223-228
[3]  
BERNSTEIN CN, 1994, LANCET, V343, P71
[4]   IMMUNOHISTOCHEMICAL DEMONSTRATION OF METALLOTHIONEIN IN NORMAL HUMAN BREAST-TISSUE AND BENIGN AND MALIGNANT BREAST-LESIONS [J].
BIER, B ;
DOUGLASJONES, A ;
TOTSCH, M ;
DOCKHORNDWORNICZAK, B ;
BOCKER, W ;
JASANI, B ;
SCHMID, KW .
BREAST CANCER RESEARCH AND TREATMENT, 1994, 30 (03) :213-221
[5]   MUTATIONS IN THE P53 GENE - AN EARLY MARKER OF NEOPLASTIC PROGRESSION IN ULCERATIVE-COLITIS [J].
BRENTNALL, TA ;
CRISPIN, DA ;
RABINOVITCH, PS ;
HAGGITT, RC ;
RUBIN, CE ;
STEVENS, AC ;
BURMER, GC .
GASTROENTEROLOGY, 1994, 107 (02) :369-378
[6]   Immunohistochemical expression of p53 and oncogenes in ulcerative colitis-associated colorectal carcinoma [J].
Brüwer, M ;
Schmid, KW ;
Senninger, N ;
Schürmann, G .
WORLD JOURNAL OF SURGERY, 2002, 26 (03) :390-396
[7]   Increased expression of metallothionein in inflammatory bowel disease [J].
Brüwer, M ;
Schmid, KW ;
Metz, KA ;
Krieglstein, CF ;
Senninger, N ;
Schürmann, G .
INFLAMMATION RESEARCH, 2001, 50 (06) :289-293
[8]  
CHERIAN MG, 1993, CANCER RES, V53, P922
[9]   METALLOTHIONEIN PROTECTS DNA FROM OXIDATIVE DAMAGE [J].
CHUBATSU, LS ;
MENEGHINI, R .
BIOCHEMICAL JOURNAL, 1993, 291 :193-198
[10]   METALLOTHIONEIN EXPRESSION IN DUCT CARCINOMA IN-SITU OF THE BREAST [J].
DOUGLASJONES, AG ;
SCHMID, KW ;
BIER, B ;
HORGAN, K ;
LYONS, K ;
DALLIMORE, ND ;
MONEYPENNY, IJ ;
JASANI, B .
HUMAN PATHOLOGY, 1995, 26 (02) :217-222